Skip to content

Fighting to Preserve the Benefits of the 340B Program

  • About Us
  • Contact Us
Top Bar Menu
Facebook page opens in new windowTwitter page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News

Author Archives: Amber Tynan

FTC Logo

RWC-340B Submits Comments to Federal Trade Commission

Drug Pricing, RegulationsBy Amber TynanApril 22, 2022

As you may know, the Federal Trade Commission recently requested public comments on the impacts of Pharmacy Benefit Managers’ practices, affecting drug affordability and access.   Today, RWC-340B submitted detailed…

Gilead

RWC-340B Sends Letters to Gilead, HHS Secretary, and OPA Director.

Congress, Drug Pricing, HHS, HRSA, Regulations, RWC-340BBy Amber TynanApril 15, 2022

A growing number of pharmaceutical manufacturers have recently posed restrictions affecting Ryan White Clinics and other Safety Net Providers. RWC-340B has taken action to address these challenges head-on.   On…

Johnson Johnson Logo

Johnson & Johnson is the 16th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies

Congress, Drug Pricing, News, RWC-340BBy Amber TynanMarch 23, 2022

By letter dated March 21, 2021, Johnson & Johnson (J&J) announced that, effective May 2, 2022, it will no longer honor bill-to/ship-to orders for contract pharmacy arrangements with hospitals unless…

Trent Smith Headshot 2022

Trent Smith hired as RWC-340B Managing Director

RWC-340BBy Amber TynanMarch 18, 2022

Trent Smith is the Managing Director for RWC-340B under UPHS and brings experience from both the nonprofit and for-profit sectors, having worked within the Southern Scholarship Foundation Community and then…

RWC 340B Logo hi res 002

RWC-340B Responds to Gilead’s Conditions on 340B Contract Pharmacy

Drug Pricing, RWC-340BBy Amber TynanMarch 17, 2022

As reported today in the 340B Report, Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy (for subscribers only), and RWC-340B President Shannon Stephenson is quoted throughout (excerpt below). Ryan White…

Gilead

Gilead to Restrict Access to 340B Prices at Contract Pharmacies for Branded Hep-C Drugs; AbbVie Adds Imbruvica to Restrictive Contract Pharmacy Policy

Drug Pricing, RWC-340BBy Amber TynanMarch 17, 2022

By letter dated March 15, 2022, Gilead announced that, effective May 2, 2022, it will implement a new “Contract Pharmacy Integrity Initiative” under which it will no longer honor  contract…

Gilead

RWC-340B Sends Gilead Letter Requesting Exceptions for MAP/PAP Policies

Drug Pricing, News, RWC-340BBy Amber TynanMarch 17, 2022

Please see the attached letter to Mr. Charles Clapton, VP of Federal Governmental Affairs with Gilead from RWC-340B President, Shannon Stephenson on behalf of RWC-340B requesting exceptions to MAP/PAP Policies. Should you…

bill 5665872 1920

Pfizer and GSK Announce Policies to Restrict Access to 340B Drugs at Contract Pharmacies; Novo Nordisk Modifies Its Policy

News, RWC-340BBy Amber TynanFebruary 16, 2022

Pfizer and GlaxoSmithKline (“GSK”) are the 13th and 14th manufacturers, respectively, to restrict 340B pricing on drugs shipped to contract pharmacies.  Novo Nordisk, which previously restricted access to 340B pricing to one…

Joe Biden

POTUS Pledges to Enforce 340B Program

News, RWC-340B, White HouseBy Amber TynanFebruary 16, 2022

President Joe Biden yesterday during a major speech on drug pricing reform applauded U.S. Rep. Abigail Spanberger (D-Va.) for being “relentless in making sure” that the 340B statute “is actually…

Hiring

RWC-340B Seeking Managing Director

NewsBy Amber TynanJanuary 26, 2022

Summary The Managing Director of the Ryan White Clinics for 340B Access Coalition (RWC-340B) reports to the Executive Director of United Partners for Human Services (UPHS), the managed service organization…

12
                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar

Accessibility Tools

  • Increase Text
  • Decrease Text
  • Grayscale
  • High Contrast
  • Negative Contrast
  • Light Background
  • Links Underline
  • Readable Font
  • Reset